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p16INK4A (p16) is the most widely used clinical biomarker for Human Papillomavirus (HPV) 
in head and neck squamous cell cancer (HNSCC). HPV is a favourable prognostic marker 
in HNSCC and is used for patient stratification. While p16 is a relatively accurate marker for 
HPV within the oropharynx, recent reports suggest it may be unsuitable for use in other 
HNSCC subsites, where a smaller proportion of tumors are HPV-driven. 
Materials & Methods: 
We integrated reverse phase protein array (RPPA) data for p16 with HPV status based on 
detection of viral transcripts by RNA-seq in a set of 210 HNSCCs profiled by The Cancer 
Genome Atlas project. Samples were queried for alterations in CDKN2A, and other pathway 
genes to investigate possible drivers of p16 expression.  
Results: 
While p16 levels as measured by RPPA were significantly different by HPV status, there 
were multiple HPV (-) samples with similar expression levels of p16 to HPV (+) samples, 
particularly at non-oropharyngeal subsites. In many cases, p16 overexpression in HPV (-) 
tumors could not be explained by mutation or amplification of CDKN2A or by RB1 mutation. 
Instead, we observed enrichment for inactivating mutations in the histone H3 lysine 36 
methyltransferase, NSD1 in HPV (-) / p16-high tumors. 
Conclusions: 
RPPA data suggest high p16 protein expression in many HPV (-) non-oropharyngeal 
HNSCCs, limiting its potential utility as an HPV biomarker outside of the oropharynx. HPV-
independent overexpression of wild-type p16 in non-oropharyngeal HNSCC may be linked 













Human papillomavirus (HPV), in particular the HPV16 subtype, represents a major 
independent risk factor for oropharyngeal carcinoma (OPSCC), a group of head and neck 
squamous cell cancers (HNSCC) affecting the tonsils and base of tongue [1-3]. This is a 
rapidly evolving cancer in the Western world, with rising trends particularly in the young [4, 
5]. The most commonly used biomarker for HPV (+) HNSCC in the clinical setting at present 
is p16INK4A (p16), encoded by the CDKN2A gene (cyclin-dependent kinase (CDK) inhibitor 
2A). p16 is overexpressed in HPV (+) HNSCC [6] and cervical cancer [7], and plays a key 
role in cell cycle control, exerting its function as a cyclin-dependent kinase (CDK) inhibitor 
by inactivating the CDKs that phosphorylate the retinoblastoma tumour suppressor protein 
(pRB), leading to a block of the cell cycle [8-10]. E7, one of two main HPV oncoproteins, 
blocks pRB’s repressive effect on the E2F transcription factors, leading to the transcription 
of S-phase genes and aberrant cell proliferation [11]. CDKN2A transcription is strongly 
upregulated in cells expressing E7 [12-15], with recent findings revealing that this is via an 
epigenetic mechanism involving histone H3 K27 demethylation by KDM6B, independent of 
pRB [16, 17]. p16 upregulation in tumour cells can therefore be a marker of active HPV 
involvement  since it is dependent upon E7 activity. This distinguishes it from HPV DNA 
detection in isolation, which indicates the presence of the virus, but does not provide 
evidence for viral oncogene expression and hence a driver role in the tumor. 
 
p16 expression detected using immunohistochemistry (IHC) exhibits a relatively high 
sensitivity and specificity as a single test of HPV activity and therefore status in 
oropharyngeal squamous cell cancer (OPSCC) [18]. Combined with E6 DNA qPCR it has 
been shown to have 97% sensitivity and 94% specificity (compared with the RNA qPCR 
"gold standard") and to be the best discriminator of favourable outcome [19], adding 
prognostic value. The recently published UICC 8th edition TNM classification institutes 
changes to the staging of oropharyngeal cancer in particular, as a reflection of this [20]. p16 
is the most widely used marker to determine HPV status and has been employed in many 
trials [21, 22] to stratify treatment of patients with OPSCC, usually without the concomitant 
use of HPV-ISH or E6 qPCR. In an attempt to define primary site of origin, p16 
overexpression detected in FNAC samples in the context of carcinoma of unknown primary 
is also recommended in the TNM 8th edition [20, 23] and is routinely tested in non-OPSCC 
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in some centres outside the US [24]. The College of American Pathologists recommends 
high-risk HPV testing for all new oropharyngeal squamous cell carcinoma patients, but it is 
not routinely recommended for head and neck carcinomas outwith the oropharynx [25]. 
 
Using TCGA data, we have recently demonstrated an HPV-dependent etiology for 
approximately 4% of non-oropharnygeal HNSCCs (non-OPSCC) [26]. Whilst HPV-targeted 
therapies such as therapeutic vaccines [27], and potentially, deintensification might be 
expected to benefit these patients, accurately identifying them requires a robust HPV assay 
suitable for use in both OPSCC and non-OPSCC. Recent studies suggest that in non-
OPSCC, where the prevalence of HPV is lower, the diagnostic performance of p16 is inferior 
[28] but more data from larger sample sets are required to confirm these initial findings. We 
hypothesized that rather than being false positives in the IHC assay, p16 protein may be 
over-expressed due to HPV-independent mechanisms in HPV (-) non-OPSCC.  To explore 
this hypothesis in a cohort for which comprehensive molecular data are available, we 
interrogated a subset of 210 HNSCCs (11 OPSCC and 199 non-OPSCC) profiled by TCGA 
in which p16 protein expression was analyzed by reverse-phase protein array (RPPA) [29].   
 




R statistical software v3.2.2 (R Core Team [30]) was used for the analysis of the data. In 
summary, we used reverse phase protein array (RPPA) data from head and neck cancer 
samples from the TCGA in combination with HPV status based on the detection of viral 
transcripts retrieved from RNA-seq analysis to examine p16INK4A protein expression in a 
set of 210 HNSCCs (Supplemental table 1), 14 of which are HPV (+). RPPA values were 
correlated against IHC in a selected subset of cases where both measures were available. 
In addition and in an attempt to understand the mechanism underlying p16 expression the 
TCGA data were further interrogated for a variety of alterations in CDKN2A, and other 
pathway genes including RB1 using matched TCGA exome sequence and copy number 
alteration data.  In an exploratory analysis, HPV (-) - p16 high samples were interrogated 
for alternative pathway alterations, including a novel association with mutations of the gene 
NSD1, which might explain elevated protein levels. In detail, RSEM-based gene expression 
quantification measurements (n = 520) and automated mutation calls (n = 508) were 
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downloaded from the Legacy Archive of the Genomic Data Commons 
(https://portal.gdc.cancer.gov/legacy-archive/search/f), while thresholded gene-level DNA 
copy number calls were downloaded from the Broad Institute’s Firehose GDAC 
(https://gdac.broadinstitute.org/).  RPPA-based measurements of p16 abundance (n = 210) 
were obtained from the cBioPortal (http:// http://www.cbioportal.org/), and HPV status was 
determined by RNA-seq analysis, as previously described [26], and associated with clinical 
data (Breakdown by status and site in supplementary data). Figures are based on 
log2(RSEM + 1) values. Scatterplots and boxplots based on gene and protein expression 
were created. Differences in expression by group were tested using a Wilcoxon Rank Sum 
test and visualization of expression values was carried out using the ggplot2 package. Copy 
number data as inferred by TCGA GISTIC analysis and mutation status were retrieved from 
the cBio portal [31] for cancer genomics (imported from the latest run of Broad's Firehose 
GDAC). Non-oropharyngeal HPV (-) HNSCCs showed similar expression levels across 
anatomical subsites and were therefore considered a single group. To search for molecular 
correlates, p16 levels (RPPA) were regressed against level 3 RNA-seq data using limma-
voom, with genes expressed at less than 1 count in at least half the dataset filtered before 
model fitting. Data were quantile normalized and significantly associated genes were 
identified at FDR < 0.05. Associations with protein abundances were established by 
regressing p16 levels against RPPA estimates for other protein abundances (Figure 3B), 
and significantly associated proteins were again defined at FDR < 0.05. Pathway analysis 
was carried out using IPA (Ingenuity Pathway Analysis) using experimentally confirmed 
interactions in human cells/tissue.  
 
p16 IHC staining and HPV-ISH 
 
p16 IHC staining was carried out in the Bond Autostainer (Leica Microsystems Inc, Norwell, 
MA, USA) according to the manufacturer’s IHC protocol. Slides were put in a 60° oven to 
remove excess paraffin. Slides were then placed in the autostainer and dewaxed in Bond 
Dewax solution (AR9222) and hydrated in Bond Wash solution (AR9590). Antigen retrieval 
was performed for 30 min at 100 °C in Bond-Epitope Retrieval solution 1 (pH 6.0, AR9961). 
Slides were then incubated with p16 antibody (mouse monoclonal anti-p16 antibody 
(MAB4133), Chemicon International Company/Millipore Corporation, Temecula, CA, USA) 
for 15 min. Antibody detection was performed using the Bond Polymer Refine Detection 
System (DS9800). Stained slides were dehydrated and coverslips added. 
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Immunohistochemical staining was performed in the Translational Pathology Lab at UNC. 
After completion of IHC, slides are stored at room temperature and a virtual scanned copy 
of all slides was obtained using the Aperio brand scanner and software. p16 immunostaining 
and HPV-ISH of archival FFPE tissue was performed on the the in-house samples (National 
Research Ethics Service Committee of East of England; reference number 12/EE/44; 




Elevated p16 levels in HPV (-) tumors at non-oropharyngeal sites: 
 
By integrating RPPA (Reverse Phase Protein Array) data for a number of proteins, including 
p16 which was made available for 210 tumors (11 OPSCC, 199 non-OPSCC, 
Supplemental Table 1) as part of the recent TCGA analysis of HNSCC [29], with 
assignment of HPV status based on E6/E7 transcript detection by RNA-seq [31, 32], we 
assessed the relationship between p16 protein expression and HPV in this cohort (see 
Supplementary Table 2 for clinical and pathological details of the analysed TCGA HNSCC 
cohort). Although p16 protein levels were significantly elevated in HPV (+) samples 
(Wilcoxon's rank sum test, P-value = 1.149e-7), multiple HPV (-) samples displayed similar 
p16 expression levels to those seen in the HPV (+) samples (Figure 1). Using the lower 
limit of p16 expression in HPV (+) tumors as the threshold for a positive test (dashed line in 
Figure 1) we determined the sensitivity, specificity, positive and negative predictive values 
in the overall population to be 100%, 79%, 27% and 100% respectively. The particularly 
unfavorable performance of p16 in non-oropharyngeal cancers for determining HPV status 
(ppv = 18% among the non-OPSCC samples in this dataset) has been previously 
demonstrated and reviewed for IHC [33], but to our knowledge this is the first dataset to 
document this by integrated genomic analysis, proving that the poor performance is not just 
a function of technical aspects of IHC reagents or staining interpretation. We considered the 
possibility that high p16 expression in HPV (-) tumors might be confined to a specific 
anatomic site but found high p16 expression in at least 15% of samples from each of the 
non-OPSCC sites, including 9 of 49 layngeal, 9 of 28 oral cavity, 4 of 20 floor of mouth and 
16 of 45 oral tongue SCCs.    
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Integration with mutation and copy number data for recurrently altered G1/S 
checkpoint pathway components 
We next considered the possibility that alterations in gene copy number for CDKN2A, such 
as amplifications might explain elevations in gene expression.  Additionally, we considered 
that aberrant signaling through other mutations in the CDK4/6 pathway might be associated 
with elevated p16 protein expression. We therefore conducted linear regression of p16 
protein levels as measured by RPPA against  mutation and copy number alteration data for 
RB1, CCND1, TP53, CDK4, CDK6 and CDKN2A, HPV status and site (oropharynx versus 
non-oropharynx). Of these factors, only HPV status (p=1.03e-07) and missense mutations 
(p=0.0205) or copy number alterations (5.68e-14) in CDKN2A itself were associated with 
p16 protein levels (Figure 2 and Supplementary Table 2). The strong association between 
CDKN2A copy number and p16 protein levels is expected due to CDKN2A deletions causing 
loss of p16 in HPV (-) disease (see samples with GISTIC copy number of -2 in Figure 2A). 
While accumulation of non-functional CDKN2A due to missense mutation may therefore 
explain its overexpression in a subset of samples, wild-type CDKN2A is observed in 24 
cases with expression of p16 equivalent to that seen in the HPV (+) tumors (Figure 1). Four 
of these tumors harbor CDKN2A amplifications, thus in 20 cases we observe high p16 
expression in the absence of missense mutations or genomic amplifications.  
 
Molecular correlates of p16 expression in HPV(+)- HNSCC.  
 
Having interrogated known G1/S checkpoint components, we next used global gene 
expression (RNA-seq) data to search for genes whose expression is associated with p16 
protein levels. Analysis of RNA-seq data identified a set of 29 genes whose expression was 
linearly associated with p16 RPPA protein levels (FDR < 0.05, Supplemental Figure 2). 
The CDKN2A gene by itself was also transcriptionally upregulated in these tumours, 
suggesting higher levels were driven transcriptionally. The scatterplot of p16 versus gene 
expression of CDKN2A demonstrated the high correlation that would be expected 
(Spearman ρ = 0.63, p < 2.2e-16), confirming the consistency of orthogonal measures of 
the biomarker (Figure 3B). Pathway analysis of this gene set using Ingenuity Pathway 
Analysis however failed to uncover significant functional associations.  Analysis of RPPA 
data identified two proteins (Yes Associated Protein (YAP) and c-Jun N-terminal Kinase 2 
(JNK2 / MAPK9), whose expression was positively associated with that of p16 (FDR < 0.05). 
Interestingly, high levels of nuclear YAP1 have previously been reported in HPV (+) OPSCC 
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cells [34].  
 
Increased expression of wild-type CDKN2A transcripts in NSD1 mutant, HPV- HNSCC. 
 
To help validate the utility of RPPA and gene expression as measures of the clinically used 
p16 IHC, we reviewed the limited representative stained samples available from the TCGA 
dataset that were definitively HPV (-), p16-high by RPPA, and elevated for CDKN2A. In all 
available cases, the p16 IHC confirmed abundant staining typical of a positive test such as 
shown in the example (Figure 3A) from the UNC TCGA cohort.   
 
Together with our observation of strong p16 IHC staining in two HPV (-) OPSCC samples 
from an independent cohort collected at University College London Hospital, UK 
(Supplemental Figure 1), these cases indicate a real upregulation of p16 protein in a subset 
of HPV (-) HNSCC. Having exhausted canonical candidate CDK4/6 pathway alterations and 
likewise largely excluded supervised gene expression biomarkers as an explanation for 
elevations in p16, we entertained exploratory candidates.  Interestingly the tumour shown 
in Figure 3A that displayed a high p16 expression harboured an inactivating mutation in the 
histone H3 lysine 36 (H3K36) methyltransferase, Nuclear Receptor Binding SET Domain 
Protein 1 (NSD1), as first reported by TCGA [29]. We then characterized p16 and CDKN2A 
expression as a function of NSD1 mutation in the full TCGA dataset, noting a clear trend for 
NSD1 mutations at the highest range of CDKN2A gene expression. Stratifying by copy 
number, HPV status and NSD1 mutational status across the expanded TCGA cohort for 
which CDKN2A transcript data are also available (n=494), CDKN2A is frequently wild-type 
and highly expressed in HPV (-) / NSD1 mutant tumours (Figure 3C). Furthermore, we 
observed significant enrichment for NSD1 mutations in CDKN2A wild-type tumors (OR = 
3.8; p-value = 0.01489, Chi square test, df =1), consistent with a scenario in which NSD1 





Although p16 is the most commonly used clinical biomarker for HPV (+) head and neck 
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cancer, our analysis would suggest specific limitations that need to be observed. There is a 
subset of HPV (-) HNSCCs where expression of p16 could lead to misidentification as HPV 
(+). A subset of the p16 (+) HPV(-) samples have p16 missense mutations, which likely 
account for accumulation of inactive p16, although insufficient samples with IHC were 
available to us to verify that such mutants are detected by IHC.  However, in other tumours, 
specific molecular alterations presumably cause, and allow the cells to tolerate, high 
expression of the wild-type p16 protein.   
 
We have provided ample and parallel data to confirm that the presence of p16 is not simply 
an artifact of inaccurate IHC, but is in fact present at high levels comparable to HPV (+) 
samples (we acknowledge the potential limitation that the number of HPV+ samples, 
compared with HPV- samples, is lower in our dataset. However, in line with previous reports 
these show significantly increased p16 expression, compared with the other groups). RB1 
mutations are not associated with high p16 levels in our analysis, consistent with recent 
data showing that HPV E7 induces p16 through upregulation of the KDM6 family H3K27 
demethylases, independent of its inhibitory effects on pRb [15]. Our finding that wild-type 
CDKN2A is frequently expressed in NSD1 mutant / HPV- tumours suggests another 
epigenetic mechanism (possibly the genome-wide accumulation of repressive histone 
(H3K27 trimethylation) marks observed upon loss of NSD1 in embryonic stem cells [35] 
through which it can be induced and tolerated in HPV (-) cells. It is the significant enrichment 
of NSD1 mutations and not a result of many other mutated genes such as RB1, as 
previously indicated, which seem to contribute to, and/or allow cells to tolerate high levels 
of functional p16 protein. The potential link between NSD1 and p16 will require further 
examination in cell-based models and larger HNSCC cohorts. Regardless of the underlying 
mechanisms, it is clear that p16 protein is expressed to the degree seen in HPV (+) HNSCC 
in a significant proportion of HPV (-), non-oropharyngeal HNSCCs. One intriguing question 
is whether the HPV (-) HNSCCs that express high levels of wild-type p16 actually become 
dependent on elevated p16 expression for their survival, as has recently been described for 
HPV (+) cells [17]. If so, this would point towards a potentially targetable vulnerability shared 
between HPV (+) and HPV (-) tumors with high p16 expression. 
These findings are of clinical relevance. Current therapies for head and neck cancer often 
carry a significant risk of long-term morbidity, including enterostomy feeding tube 
dependence, osteoradionecrosis, pharyngo-oesophageal fibrosis leading to dysphagia, 
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xerostomia, dental failure, hypothyroidism, vascular destruction with associated late 
occurring strokes and carotid stenosis as well as treatment induced tumours. All these 
effects/risks are directly related to radiation therapy – therefore reducing the dose exposure 
is of great therapeutic interest. The de-escalation of therapeutic intensity in HPV (+) disease 
is currently being tested in clinical trials, such as RTOG 1016, De-ESCALaTE, Quarterback, 
TROG-12.01, ADEPT, ECOG 3311 and PATHOS (recently reviewed in [36]). 
 
However, as the current study suggests, there is some risk in the use of p16 as the 
biomarker for HPV status, whether in the oropharynx or other anatomic location. Before 
selection of the most appropriate therapy, either escalation for high risk patients or de-
escalation for lower risk HPV (+) cases, patients deserve a more accurate assay such as 
directly for the presence of HPV (by e.g. ISH, qPCR, RNA FISH or qRT-PCR). This is of 
particular relevance in view of the recently published 8th edition TNM classification which 
institutes changes to the staging of oropharyngeal cancer in particular, as a reflection of this, 
which distinguishes between e.g. nodal status of HPV(+) and HPV(-) OPSCC, but p16 
staining or other forms of HPV testing are not stipulated except for FNAC specimens from 
metastatic neck nodes [20]. This appears particularly true for non-OPSCC. The American 
Society of Pathologists does not recommend the routine testing of nonsquamous 
oropharyngeal carcinomas or nonoropharyngeal carcinomas for HPV [25]. In summary, the 
decision for any de-escalation of therapeutic intensity must not be made on a p16 staining 
result alone, especially in view of potential extension of current de-escalation trials to other 
head and neck subsites [28, 37, 38].  
In summary, we show that HPV (-) HNSCCs at non-oropharyngeal subsites frequently 
express levels of p16 protein seen in HPV (+) oropharyngeal tumors. We show that p16 
expression is not due to genomic alterations in RB1 or other components of the G1/S cell 
cycle checkpoint, nor can it be explained by mutations in p16 (CDKN2A) itself. Instead we 
find an association with mutations in the histone methyltransferase, NSD1, which (like p16 
expression) have been linked to improved prognosis in HNSCC [39]. Our observations 
reinforce the need for alternative HPV biomarkers to complement p16, particularly beyond 
the oropharynx, and suggest a hitherto unexplored connection between NSD1 mutation and 
p16 upregulation in HPV (-) HNSCC.  
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Age   
 Mean = 62.14  
 Standard deviation = 12.28  
   
Gender   
 Female - 61  
 Male - 149  
   
Ethnicity   
 Hispanic/Latino - 13  
 Not Hispanic/Latino - 188  
   
Histology   
 Head and neck squamous cell carcinoma - 210  
   
Site   
 Alveolar ridge – 6  HPV(-) 4, HPV(+) 2 
 Base of tongue – 6  HPV(-) 4, HPV(+) 2 
 Buccal mucosa – 7  HPV(-) 7, HPV(+) 0 
 Floor of mouth – 24  HPV(-) 24, HPV(+) 0 
 Hard palate – 3  HPV(-) 2, HPV(+) 1 
 Hypopharynx – 1  HPV(-) 1, HPV(+) 0 
 Larynx – 58 HPV(-) 57, HPV(+) 1 
 Lip – 2  HPV(-) 2, HPV(+) 0 
 Oral cavity – 37  HPV(-) 36, HPV(+) 1 
 Oral tongue – 61  HPV(-) 57, HPV(+) 4 
 Oropharynx – 1  HPV(-) 1, HPV(+) 0 
 Tonsil – 4  HPV(-) 1, HPV(+) 3 
 
Supplementary Table 1: Details on the head and neck cancer samples of the TCGA 























CDKN2A CNA 0.484486 0.06152 7.875 5.68E-14 *** 
CDK4 CNA 0.00571 0.105709 0.054 0.957 
 
CDK6 CNA -0.00554 0.076725 -0.072 0.9425 
 
RB1 CNA 0.002373 0.07957 0.03 0.9762 
 
CCND1 CNA 0.032629 0.058314 0.56 0.5762 
 
CDKN2A MUTATION 0.336628 0.144547 2.329 0.0205 * 
TP53 MUTATION 0.009346 0.157208 0.059 0.9526 
 
RB1 MUTATION -0.0677 0.351622 -0.193 0.8474 
 
HPV POSITIVE 1.504397 0.276084 5.449 1.03E-07 *** 
SUBSITE - OROPHARYNX -0.3045 0.206869 -1.472 0.142 
 
 
Supplementary Table 2: Linear model coefficients from a regression of p16 protein levels 









     
Supplemental Figure 1: Examples of p16 immunohistochemistry and HR HPV-DNA-ISH 
non-concordant results. Patient A, upper slide, p16 positive tumour by 
immunohistochemistry showing strong nuclear and cytoplasmic staining (×400); lower slide, 
HR HPV negative tumour by ISH (×600). Patient B, upper slide shows a p16 negative tumor 
by immunohistochemistry (×400); lower slide, HR HPV positive tumor by ISH (×600). These 
results are in line with RT-qPCR results for high-risk HPV RNA, obtained from the same 
samples. The p16INK4a IHC was carried out on FFPE tissue using a mouse mAb (BD 
Biosciences, Franklin Lakes, NJ, USA), as described previously (L. Masterson et al., 
Investigating the role of human papillomavirus in squamous cell carcinoma of the temporal 
bone. Head Neck Oncol 2013; 5(2): 22). DNA in situ hybridization consisted of a probe 
directed against high-risk HPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66 
(INFORM HPV III; Ventana, Tucson, AZ, USA), as described previously (T. Grogan, 
Interpretation Guide for Ventana INFORM HPVzr Probes In Situ Hybridization (ISH) Staining 
of Cervical Tissue; 2006). 
 4 
 
Supplemental Figure 2: Analysis of RNA-seq data using limma-voom identified a set of 
29 genes whose expression was linearly associated with p16 RPPA protein levels (FDR < 
0.05). 
 
 
 
 
 
